Literature DB >> 16820091

Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer.

Shuji Ogino1, Mohan Brahmandam, Takako Kawasaki, Gregory J Kirkner, Massimo Loda, Charles S Fuchs.   

Abstract

Cyclooxygenase-2 (COX-2) overexpression and mutations of p53 (a known COX-2 regulator) are inversely associated with microsatellite instability-high (MSI-H) and CpG island methylator phenotype (CIMP) characterized by extensive promoter methylation, is associated with MSI-H. However, no studies have comprehensively examined interrelations between COX-2, p53, MSI, and CIMP. Using MethyLight, we measured DNA methylation in five CIMP-specific gene promoters [CACNA1G, CDKN2A (p16/INK4A), CRABP1, MLH1, and NEUROG1] in relatively unbiased samples of 751 colorectal cancer cases obtained from two large prospective cohorts; 115 (15%) tumors were CIMP-high (> or = 4 of 5 methylated promoters), 251 (33%) were CIMP-low (1 to 3 methylated promoters), and the remaining 385 (51%) were CIMP-0 (no methylated promoters). CIMP-high tumors were much less frequent in COX-2+/p53+ tumors (4.6%) than in COX-2+/p53- tumors (19%; P < .0001), COX-2-/p53+ tumors (17%; P = .04), and COX-2-/p53- tumors (28%; P < .0001). In addition, COX-2+/p53+ tumors were significantly less common in MSI-H CIMP-high tumors (9.7%) than in non-MSI-H CIMP-low/CIMP-0 tumors (44-47%; P < .0001). In conclusion, COX-2 and p53 alterations were synergistically inversely correlated with both MSI-H and CIMP-high. Our data suggest that a combined analysis of COX-2 and p53 may be more useful for the molecular classification of colorectal cancer than either COX-2 or p53 analysis alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820091      PMCID: PMC1601473          DOI: 10.1593/neo.06247

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  48 in total

1.  Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype.

Authors:  M Toyota; M Ohe-Toyota; N Ahuja; J P Issa
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  CpG island methylation in aberrant crypt foci of the colorectum.

Authors:  Annie On-On Chan; Russell R Broaddus; Patrick S Houlihan; Jean-Pierre J Issa; Stanley R Hamilton; Asif Rashid
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

3.  CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.

Authors:  Nicholas Hawkins; Mark Norrie; Kay Cheong; Elisa Mokany; Su-Lyn Ku; Alan Meagher; Terence O'Connor; Robyn Ward
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

4.  Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer.

Authors:  W S Samowitz; J A Holden; K Curtin; S L Edwards; A R Walker; H A Lin; M A Robertson; M F Nichols; K M Gruenthal; B J Lynch; M F Leppert; M L Slattery
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 5.  Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer.

Authors:  M A Rubin
Journal:  J Pathol       Date:  2001-09       Impact factor: 7.996

6.  Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands.

Authors:  M van Rijnsoever; F Grieu; H Elsaleh; D Joseph; B Iacopetta
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

7.  Validation of tissue microarray technology in breast carcinoma.

Authors:  R L Camp; L A Charette; D L Rimm
Journal:  Lab Invest       Date:  2000-12       Impact factor: 5.662

8.  alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.

Authors:  Mark A Rubin; Ming Zhou; Saravana M Dhanasekaran; Sooryanarayana Varambally; Terrence R Barrette; Martin G Sanda; Kenneth J Pienta; Debashis Ghosh; Arul M Chinnaiyan
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

9.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.

Authors:  S Ogino; M Cantor; T Kawasaki; M Brahmandam; G J Kirkner; D J Weisenberger; M Campan; P W Laird; M Loda; C S Fuchs
Journal:  Gut       Date:  2006-01-11       Impact factor: 23.059

10.  Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors.

Authors:  M Toyota; L Shen; M Ohe-Toyota; S R Hamilton; F A Sinicrope; J P Issa
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

View more
  49 in total

Review 1.  Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.

Authors:  Katsuhiko Nosho; Yoshifumi Baba; Noriko Tanaka; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Edward Giovannucci; Glenn Dranoff; Charles S Fuchs; Shuji Ogino
Journal:  J Pathol       Date:  2010-12       Impact factor: 7.996

Review 2.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

Review 3.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

4.  Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype.

Authors:  K Nosho; T Kawasaki; A T Chan; M Ohnishi; Y Suemoto; G J Kirkner; C S Fuchs; S Ogino
Journal:  Histopathology       Date:  2008-11       Impact factor: 5.087

Review 5.  Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.

Authors:  Kaori Shima; Katsuhiko Nosho; Yoshifumi Baba; Mami Cantor; Jeffrey A Meyerhardt; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

6.  Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.

Authors:  Takako Kawasaki; Katsuhiko Nosho; Mutsuko Ohnishi; Yuko Suemoto; Gregory J Kirkner; Reiko Dehari; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

7.  Cohort study of fatty acid synthase expression and patient survival in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Jeffrey A Meyerhardt; Gregory J Kirkner; Andrew T Chan; Takako Kawasaki; Edward L Giovannucci; Massimo Loda; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

8.  Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer.

Authors:  Akiko Hanyuda; Sun A Kim; Alejandro Martinez-Fernandez; Zhi Rong Qian; Mai Yamauchi; Reiko Nishihara; Teppei Morikawa; Xiaoyun Liao; Kentaro Inamura; Kosuke Mima; Yin Cao; Xuehong Zhang; Kana Wu; Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs; Ramesh A Shivdasani; Shuji Ogino
Journal:  Ann Surg Oncol       Date:  2015-11-17       Impact factor: 5.344

9.  Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.

Authors:  Yoshifumi Baba; Curtis Huttenhower; Katsuhiko Nosho; Noriko Tanaka; Kaori Shima; Aditi Hazra; Eva S Schernhammer; David J Hunter; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Mol Cancer       Date:  2010-05-27       Impact factor: 27.401

10.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.